Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly pill aims to keep weight off after obesity treatment

NCT ID NCT07553299

Disease control Sponsor: Verdiva Bio Dev Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests a weekly oral medication called ecnoglutide (VRB-101) to see if it can help people with obesity or overweight maintain their weight. Participants must have already been on weekly injections of semaglutide or tirzepatide for at least 6 months. The goal is to find the best dose for weight maintenance while monitoring safety and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a history of BMI of ≥30 kg/m2 OR ≥27 kg/m2 and \<30 kg/m2 with at least 1 weight-related comorbidity at the time of initiation of subcutaneous (SC) semaglutide and/or tirzepatide treatment. * Documented history of having obesity or overweight with weight-related comorbidities per medical records at the time of initiation of SC semaglutide and/or tirzepatide treatment. * History of treatment with weekly SC semaglutide and/or tirzepatide for a minimum of 6 months prior to Screening. * Documented weight reduction of ≥10% in 6 months and no clinically relevant weight regain. * Participants of childbearing potential (POCBP) must be non-pregnant and non-lactating and must agree to use study-specified contraceptive methods. Exclusion Criteria: * Current or past diagnosis of diabetes mellitus \[type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or other forms of diabetes mellitus\]. A participant with a history of gestational diabetes may be included in the study if the participant has HbA1c \<6.5% at Screening and is not on medication to lower glucose. * At least 1 laboratory value suggestive of diabetes during screening, including 1 or more of HbA1c ≥6.5% (48 mmol/mol) or random glucose ≥200 mg/dL (11.1 mmol/L). * Diagnosed with obesity due to endocrinologic disorders (for example, Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency or Prader-Willi syndrome) * History of clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction). * Evidence of uncontrolled hypothyroidism or hyperthyroidism based on an abnormal thyroid-stimulating hormone (TSH). * Personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma. * Evidence of a significant, uncontrolled endocrine abnormality (for example, thyrotoxicosis or adrenal crises) * Renal impairment measured as eGFR \<30 mL/min/1.73 m2 * History of acute or chronic pancreatitis or clinically significant gallbladder disease. * Triglycerides \>500 mg/dL (5.7 mmol/L) at Screening. * Poorly controlled hypertension or an elevated resting pulse rate (\>100 bpm). * Current treatment with or history of treatment with (within 3 months prior to Screening) medications that may cause significant weight gain. * Prior or planned surgical treatment for obesity, plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to Screening. * Known hypersensitivity to any of the study drug ingredients. * Are pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study and for at least 60 days after completion of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight Weight maintenance

Contacts and locations

Locations

  • Clinical Study Site 201

    Little Rock, Arkansas, 72205, United States

  • Clinical Study Site 202

    Cullman, Alabama, 35055, United States

  • Clinical Study Site 203

    Phoenix, Arizona, 85028, United States

  • Clinical Study Site 204

    Bradenton, Florida, 34209, United States

  • Clinical Study Site 205

    Buffalo, New York, 14217, United States

  • Clinical Study Site 206

    Lenoir, North Carolina, 28645, United States

  • Clinical Study Site 207

    Richmond, Virginia, 23226, United States

  • Clinical Study Site 209

    Jackson, Tennessee, 38305, United States

  • Clinical Study Site 210

    Petal, Mississippi, 39465, United States

  • Clinical Study Site 211

    Houston, Texas, 77040, United States

  • Clinical Study Site 212

    Tempe, Arizona, 85281, United States

  • Clinical Study Site 213

    El Dorado, Kansas, 67042, United States

  • Clinical Study Site 214

    Santa Maria, California, 93454, United States

  • Clinical Study Site 215

    St. Petersburg, Florida, 33704, United States

  • Clinical Study Site 216

    Stamford, Connecticut, 06905, United States

  • Clinical Study Site 217

    Houston, Texas, 77008, United States

  • Clinical Study Site 218

    Irving, Texas, 75063, United States

  • Clinical Study Site 219

    Niles, Illinois, 60714, United States

  • Clinical Study Site 220

    Oklahoma City, Oklahoma, 73111, United States

  • Clinical Study Site 221

    Orange City, Florida, 32763, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.